quarter update- focu tripl cf landscap
vertex report cystic fibrosi cf product revenu
miss consensu beat bottom line non-gaap
ep vs kalydeco orkambi symdeko revenu came
respect vertex end period
guidanc reiter product revenu opex
 non-gaap opex
doublet franchis orkambi symdeko continu grow await
tripl combin revenu two product q/q
increas beat consensu expect continu
see revenu growth shift orkambi symdeko approv symkevi
symdeko eu expect quarter
note see data readout form compet doublet particularli
proteostasi pti nr demonstr posit data albeit small
number patient pti tripl data come galapago also
earli stage data doublet although data similar orkambi
movement tripl addit effect
conclus vertex remain well ahead competitor tripl
alreadi head toward pivot data year nda expect
cf franchis continu grow vertex maintain domin
space
proteostasi inc pti nr doublet data wait-n-se stori
oct pti report new data three doublet cohort on-going
trial del homozyg patient patient dose
corrector potenti move triplet therapi
amplifi next total patient dose
three differ cohort doublet
respect receiv placebo fourth highest dose
on-going doublet data look good numer hard
tell small valu mid-dos group experienc benefit
increas day day doublet tripl data
galapago nv glpg nr glpg also announc top-line data on-going
falcon studi potenti del
homozyg cf patient week treatment result mean increas
baselin line orkambi decreas sweat chlorid
critic addit corrector tripl combin
result enhanc cftr activ long-term follow-up expect
interestingli nr announc obtain exclus
right galapago cf portfolio
vertex treatment orkambi del homozyg shown placebo-
adjust improv day longer durat larger patient
number symdeko demonstr vertex two tripl phase
studi prior data improv symdeko
model chang base chang tax law adjust model
go forward incorpor tax rate chang
model also made regard opex net effect ep estim
lower
thousand except per share data
interest incom net
loss discontinu oper
net incom attribut vertex
compani report maxim group estim
